Video Experimental Relacionado
Updated: Aug 14, 2026
08:58
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Aumento de la síntesis de óxido nítrico en la colitis ulcerosa
S J Middleton1, M Shorthouse, J O Hunter
1Department of Gastroenterology, Addenbrooke's Hospital, Cambridge, UK.
Lancet (London, England)
|February 20, 1993
Resumen
El aumento de la producción de óxido nítrico (NO), indicado por niveles más altos de citrulina, se observó en la colitis ulcerosa activa. Esto sugiere que el NO puede jugar un papel en la enfermedad.
Área de la Ciencia:
- Gastroenterología y Gastroenterología.
- Inmunología Inmunología.
- La bioquímica es la bioquímica.
Sus antecedentes:
- El óxido nítrico (NO) es sintetizado por la NO sintasa, liberando citrulina.
- La colitis ulcerosa (UC) es una enfermedad inflamatoria intestinal crónica que afecta al colon.
Objetivo del estudio:
- Investigar el papel de la biosíntesis del óxido nítrico (NO) en la colitis ulcerosa activa (UC).
- Para determinar si la producción de NO está elevada en los tejidos de UC.
Principales métodos:
- Se midieron las concentraciones de citrulina en muestras de biopsia rectal de pacientes con UC activa, UC en reposo e histología normal.
- Muestras de biopsia de UC incubadas con NG-monometil-L-arginina (L-NMMA) para evaluar su efecto en la producción de citrulina.
Principales resultados:
- Las concentraciones de citrulina fueron significativamente más altas en las biopsias UC activas en comparación con la UC en reposo o la histología normal.
- La inhibición de la NO sintasa por L-NMMA redujo la producción de citrulina en muestras de biopsia de UC.
Conclusiones:
- La biosíntesis de NO mucosal se incrementa en la colitis ulcerosa activa.
- La producción elevada de NO puede contribuir a la patogénesis de la colitis ulcerosa.
Videos de Conceptos Relacionados
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:28Peptic Ulcer Disease II: Pathophysiology
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
01:24Peptic Ulcer Disease II: Pathophysiology
Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...